Introduction {#Sec1}
============

Severe sepsis induces a state of immunoparalysis.\[[@CR1]\] Animal models have demonstrated this to be secondary to microbial-induced host epigenetic alterations, which persist and are associated with long-term immunoparalysis.\[[@CR2]\] Whilst human sepsis is associated with poor long-term outcomes in conjunction with recurrent infections,\[[@CR3]\] it is not clear if the immunoparalysed state persists following recovery from the initial septic insult.

Objectives {#Sec2}
==========

1\. To confirm the presence of circulating mediators capable of causing immunoparalysis following bacteraemia.

2\. To assess for the presence of immunosuppressive mediators following hospital discharge with full functional recovery.

Methods {#Sec3}
=======

Consecutive adult patients (n = 7) with bacteraemia and an admission diagnosis of infection were recruited. Serum was collected at 3 time points; within 48 hours of the positive blood culture, 5 days later & 12 months following hospital discharge. Peripheral blood mononuclear cells (PBMCs) were collected from a healthy control cohort (n = 7) and pooled. Healthy PBMCs were co-cultured with 30% septic serum for 20 hours with and without GM-CSF (200ng/ml). CD14^+^HLA-DR (mHLA-DR) geometric-mean fluorescent intensity (MFI) was determined using flow cytometry. Data were analysed with non-parametric statistics with results presented as median & IQR .

Results {#Sec4}
=======

Three patients required ICU care & four were managed on the ward. Demographic & clinical data are presented in Figure [2](#Fig2){ref-type="fig"}. mHLA-DR levels were lower when PBMCs were co-cultured with the baseline bacteraemic sample in comparison with control group serum (Figure [1](#Fig1){ref-type="fig"}, *P* = 0.01). mHLA-DR levels following co-culture with the baseline sample were not significantly different to the levels observed when co-cultured with day 5 serum (Figure [1A](#Fig1){ref-type="fig"}). in comparison to the baseline sample, when co-cultured with serum from 12 months, mHLA-DR levels were increased (Figure [1A](#Fig1){ref-type="fig"}, *P* = 0.007). mHLA-DR levels at 12 months were not different from those seen when control serum was used (Figure [1A](#Fig1){ref-type="fig"}*P* = 0.85). mHLA-DR levels were higher in the presence of GM-CSF when co-cultured with baseline (Figure [1B](#Fig1){ref-type="fig"}, *P* = 0.01) and 12 month (Figure [1B](#Fig1){ref-type="fig"}, *P* = 0.02) samples but not with day 5 serum (Figure [1B](#Fig1){ref-type="fig"}, *P* = 0.17).Figure 1Figure 2**Demographic and clinical details of patients requiring ICU care (severe sepsis) and those receiving ward based care (no organ impairment).**

Conclusions {#Sec5}
===========

Circulating mediators present in the serum of bacteraemic patients reduces the ability of healthy monocytes to express cell surface HLA-DR, which is reversible in the presence of an immunostimulant. Serum from patients following full recovery from the acute illness does not reduce HLA-DR expression on healthy monocytes.

Grant Acknowledgment {#Sec6}
====================

ESICM Basic Science Award 2014.
